Head-to-head comparison of four COVID-19 vaccines on platelet activation, coagulation and inflammation. The TREASURE study.

Autor: Brambilla M; Centro Cardiologico Monzino IRCCS, Milan, Italy., Canzano P; Centro Cardiologico Monzino IRCCS, Milan, Italy., Valle PD; Coagulation Service and Thrombosis Research Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy., Becchetti A; Centro Cardiologico Monzino IRCCS, Milan, Italy., Conti M; Centro Cardiologico Monzino IRCCS, Milan, Italy., Alberti M; Centro Cardiologico Monzino IRCCS, Milan, Italy., Galotta A; Centro Cardiologico Monzino IRCCS, Milan, Italy., Biondi ML; Centro Cardiologico Monzino IRCCS, Milan, Italy., Lonati PA; Istituto Auxologico Italiano IRCCS, Milan, Italy., Veglia F; Maria Cecilia Hospital, Cotignola, RA, Italy., Bonomi A; Centro Cardiologico Monzino IRCCS, Milan, Italy., Cosentino N; Centro Cardiologico Monzino IRCCS, Milan, Italy., Meroni PL; Istituto Auxologico Italiano IRCCS, Milan, Italy., Zuccotti GV; Department of Pediatrics, Vittore Buzzi Children's Hospital, Università degli Studi di Milano, Milan, Italy., D'Angelo A; Coagulation Service and Thrombosis Research Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy., Camera M; Centro Cardiologico Monzino IRCCS, Milan, Italy; Department of Pharmaceutical Sciences, Università degli Studi di Milano, Milan, Italy. Electronic address: marina.camera@unimi.it.
Jazyk: angličtina
Zdroj: Thrombosis research [Thromb Res] 2023 Mar; Vol. 223, pp. 24-33. Date of Electronic Publication: 2023 Jan 18.
DOI: 10.1016/j.thromres.2023.01.015
Abstrakt: Introduction: Studies exploring alterations in blood coagulation and platelet activation induced by COVID-19 vaccines are not concordant. We aimed to assess the impact of four COVID-19 vaccines on platelet activation, coagulation, and inflammation considering also the immunization dose and the history of SARS-CoV-2 infection.
Methods: TREASURE study enrolled 368 consecutive subjects (161 receiving viral vector vaccines -ChAdOx1-S/Vaxzevria or Janssen- and 207 receiving mRNA vaccines -Comirnaty/Pfizer-BioNTech or Spikevax/Moderna). Blood was collected the day before and 8 ± 2 days after the vaccination. Platelet activation markers (P-selectin, aGPIIbIIIa and Tissue Factor expression; number of platelet-monocyte and -granulocyte aggregates) and microvesicle release were analyzed by flow cytometry. Platelet thrombin generation (TG) capacity was measured using the Calibrated Automated Thrombogram. Plasma coagulation and inflammation markers and immune response were evaluated by ELISA.
Results: Vaccination did not induce platelet activation and microvesicle release. IL-6 and CRP levels (+30%), D-dimer, fibrinogen and F 1 +2 (+13%, +3.7%, +4.3%, respectively) but not TAT levels significantly increased upon immunization with all four vaccines, with no difference among them and between first and second dose. An overall minor post-vaccination reduction of aPC, TM and TFPI, all possibly related to endothelial function, was observed. No anti-PF4 seroconversion was observed.
Conclusion: This study showed that the four COVID-19 vaccines administered to a large population sample induce a transient inflammatory response, with no onset of platelet activation. The minor changes in clotting activation and endothelial function might be potentially involved at a population level in explaining the very rare venous thromboembolic complications of COVID-19 vaccination.
Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2023. Published by Elsevier Ltd.)
Databáze: MEDLINE
Externí odkaz: